Capecitabine is used for: Breast cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer.
Recorded in the NepalDoc medicine catalog for Capecitabine.
Capecitabine tablet is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer, adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen., perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy., treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen.
From the U.S. FDA-approved label for Capecitabine. Full label: DailyMed.
Capecitabine tablet is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer, adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen., perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy., treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. Gastric, Esophageal, or Gastroesophageal Junction Cancer, treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen., treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. Pancreatic Cancer, adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
From the U.S. FDA-approved label for Capecitabine. Full label: DailyMed.
Adjuvant Treatment of Colon Cancer, Single agent: 1,250 mg/m 2 twice daily orally for the first 14 days of each 21-day cycle for a maximum of 8 cycles. In combination with Oxaliplatin-Containing Regimens: 1,000 mg/m 2 orally twice daily for the first 14 days of each 21-day cycle for a maximum of 8 cycles in combination with oxaliplatin 130 mg/m 2 administered intravenously on day 1 of each cycle.
Directions from the U.S. FDA-approved label for Capecitabine — your doctor or pharmacist may advise differently.
Capecitabine tablets are contraindicated in patients with history of severe hypersensitivity reaction to fluorouracil or capecitabine. History of severe hypersensitivity reactions to fluorouracil or capecitabine
Excerpt from the U.S. FDA-approved label for Capecitabine. Talk to a pharmacist or doctor before use.
Cardiotoxicity: May be more common in patients with a prior history of coronary artery disease. Withhold capecitabine tablets for cardiotoxicity as appropriate. The safety of resumption of capecitabine tablets in patients with cardiotoxicity that has resolved has not been established., Diarrhea: Withhold capecitabine tablets and then resume at same or reduced dose, or permanently discontinue, based on severity and occurrence., Dehydration: Optimize hydration before starting capecitabine tablets. Monitor hydration status and kidney function at baseline and as clinically indicated.
Warnings and precautions excerpt from the U.S. FDA-approved label for Capecitabine — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are described elsewhere in the labeling: Cardiotoxicity Diarrhea Dehydration Renal Toxicity Serious Skin Toxicities Palmar-Plantar Erythrodysesthesia Syndrome Myelosuppression Hyperbilirubinemia, Most common adverse reactions in patients who received capecitabine tablets as a single agent for the adjuvant treatment for colon cancer (>30%) were palmar-plantar…
Excerpt from the U.S. FDA-approved label for Capecitabine — not a complete list. Talk to a pharmacist or doctor about side effects.
5 brands · 5 makers in the NepalDoc catalog — see the full Capecitabine guide →
Store at 20° to 25°C (68° to 77°F).. KEEP TIGHTLY CLOSED.
Storage information from the U.S. FDA-approved label for Capecitabine.
What is Xeloda?
Xeloda 500mg Tablet is a Capecitabine medicine made by ROCHE Pharma. It comes as 500mg Tablet.
What is Xeloda used for?
Capecitabine is used for Breast cancer, Colorectal cancer, Gastric cancer, Oesophageal cancer.
What is the generic name of Xeloda?
The generic name of Xeloda is Capecitabine.
Which brands of Capecitabine are available in Nepal?
5 brands of Capecitabine are listed in the NepalDoc catalog, from 5 makers — including C-Xelocel 500mg Tablet, Capcibin 500mg Tablet, Capegard 500 mg Tablet, Citabin 500mg Tablet.
What are the side effects of Capecitabine?
The following clinically significant adverse reactions are described elsewhere in the labeling: Cardiotoxicity Diarrhea Dehydration Renal Toxicity Serious Skin Toxicities Palmar-Plantar Erythrodysesthesia Syndrome Myelosuppression Hyperbilirubinemia, Most common adverse reactions in patients who received capecitabine tablets as a single agent for the adjuvant treatment for colon cancer (>30%) were palmar-plantar…
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
